(2S,5R,6R)-3,3-二甲基-7-氧代-6-[(2-苯氧基乙酰基)氨基]-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸钙 | 147-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 中文名称: (2S,5R,6R)-3,3-二甲基-7-氧代-6-[(2-苯氧基乙酰基)氨基]-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸钙
• 中文别名: [2S-cis(2α,5α,6β)]-二[3,3-二甲基-7-羰基-6-[(苯氧乙基)氨基]-4-硫-1-氮杂双环[3.2.0]庚烷-2-甲酯]钙盐
• CAS: 147-48-8
• 化学式: C16H18CaN2O5S
• 分子量: 390.5
• InChiKey: SRDSZOAVXFSUSX-LQDWTQKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.32
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Urethral catheter capable of preventing urinary tract infection and process for producing the same
  申请人：UNITIKA LTD.

  公开号：EP0065884A1

  公开（公告）日：1982-12-01

  A urethral catheter composed of olefin polymer, diene polymer or silicone polymer as a base material wherein an antimicrobial substance being chemically bonded with the inside wall and/or the outside wall thereof, and a process for producing the same. This urethral catheter effectively prevents urinary tract infection for a long period of time.

  一种以烯烃聚合物、二烯聚合物或硅酮聚合物为基材，在其内壁和/或外壁化学键合抗菌物质的尿道导管及其生产工艺。 这种尿道导管可长期有效地防止尿路感染。
• An otorhinological drug delivery device
  申请人：Schering Oy

  公开号：EP1438942A1

  公开（公告）日：2004-07-21

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的芯体，其中所述芯体由弹性体组合物制成，该弹性体组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元S原子上的3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧烷）基团）及其混合物组成的组。
• Method of treating benign prostatic hyperlasia with antibiotics
  申请人：Nymox Corporation

  公开号：US10835538B2

  公开（公告）日：2020-11-17

  Disclosed are methods of improving the symptoms of mammals suffering from BPH using compositions containing one or more antibiotics. The method includes, but is not limited to, administering at least one antibiotic in one or more courses of treatment by one or more administration routes selected from intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, and transdermally, either alone or with a carrier to a mammal in need thereof.

  本发明公开了使用含有一种或多种抗生素的组合物改善患有前列腺增生症的哺乳动物症状的方法。该方法包括，但不限于，在一个或多个疗程中，通过选自肌肉注射、口服、静脉注射、鞘内注射、瘤内注射、鼻内注射、局部注射和透皮注射的一种或多种给药途径，单独或与载体一起给需要的哺乳动物施用至少一种抗生素。
• Otorhinological delivery device
  申请人：Haapakumpu Timo

  公开号：US20060067982A1

  公开（公告）日：2006-03-30

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Siatoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof, and a membrane encasing said core, said membrane being made of a same or a different elastomer composition than said core, said elastomer composition being selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Siatoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof. The invention is characterized in that the pharmaceutically active agent is selected from the group comprising anti-allergic agents, anti-inflammatory agents, anti-fungicides, glucocorticoids and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的核心，其中所述核心由弹性体组合物制成，该组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元硅原子上的 3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧亚烷基）基团）及其混合物组成的组、以及包覆所述芯材的膜，所述膜由与所述芯材相同或不同的弹性体组合物制成，所述弹性体组合物选自聚二甲基硅氧烷、硅氧烷单元硅原子上附有 3,3,3-三氟丙基的硅氧烷基弹性体、聚环氧烷基硅氧烷基弹性体及其混合物组成的组。本发明的特征在于，药物活性剂选自抗过敏剂、抗炎剂、抗真菌剂、糖皮质激素及其混合物。
• METHOD OF TREATING BENIGN PROSTATIC HYPERLASIA WITH ANTIBIOTICS
  申请人：Nymox Corporation

  公开号：EP3743089A1

  公开（公告）日：2020-12-02